TP53INP1 and acute myeloid leukemia: miR-155 has been demonstrated to be dysregulated in different types of malignancies, such as cervical cancer,[16] breast cancer,[17] colon cancer,[18] gastric cancer,[19] as well as AML.[20] In cervical cancer, miR-155 promotes malignant tumor cell phenotypes through direct targeting of TP53INP1.[21] Additionally, miR-155 is overexpressed in AML and was identified as a potential biomarker for detecting AML.[22] Wang[23] et al. demonstrated that miR-146a can promote cell proliferation and suppresses cell apoptosis via the downregulation of CNTFR in AML and ALL.